Wael A. Harb

3.4k total citations · 1 hit paper
118 papers, 2.5k citations indexed

About

Wael A. Harb is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wael A. Harb has authored 118 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 38 papers in Molecular Biology. Recurrent topics in Wael A. Harb's work include Lung Cancer Treatments and Mutations (29 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Wael A. Harb is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), HER2/EGFR in Cancer Research (18 papers) and Cancer Immunotherapy and Biomarkers (17 papers). Wael A. Harb collaborates with scholars based in United States, Canada and France. Wael A. Harb's co-authors include Tony Tran, Andrea Fan, Michael A. Schwartz, David N. Keys, Daniel C. Danila, Cristian Ionescu‐Zanetti, Francis P. Arena, Howard A. Burris, Wentao Feng and Kathleen I. Pritchard and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Wael A. Harb

117 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

2013 383 citations Wael A. Harb et al. profile →

Peers

Countries citing papers authored by Wael A. Harb

Since Specialization

Citations

This map shows the geographic impact of Wael A. Harb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wael A. Harb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wael A. Harb more than expected).

Fields of papers citing papers by Wael A. Harb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wael A. Harb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wael A. Harb. The network helps show where Wael A. Harb may publish in the future.

Co-authorship network of co-authors of Wael A. Harb

This figure shows the co-authorship network connecting the top 25 collaborators of Wael A. Harb. A scholar is included among the top collaborators of Wael A. Harb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wael A. Harb. Wael A. Harb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE) 2023 ·Journal for ImmunoTherapy of Cancer ·Marwan Fakih, Wael A. Harb, Daruka Mahadevan, Hani M. Babiker, Jordan Berlin, Tom Lillie, David Krige, (unknown), Chris D. Cox, Minesh Patel, (unknown), Mark Powell, Lee S. Rosen	28
2	Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial 2023 ·ESMO Open ·Jordi Rodón, Daniel Shao-Weng Tan, Ignacio Garrido‐Laguna, Wael A. Harb, Alberto Bessudo, J. Thaddeus Beck, Sylvie Rottey, Nathan Bahary, Nuria Kotecki, Zezhang Zhu, Shibing Deng, Karey Kowalski, C. Wei, Nazima Pathan, Robert J Laliberte, Wells A. Messersmith	8
3	Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer 2021 ·Journal of Clinical Oncology ·Aditya Bardia, Virginia Kaklamani, Sharon Wilks, Amy Weise, Donald Richards, Wael A. Harb, Cynthia R. Osborne, Robert Wesolowski, Meghan Karuturi, Paul Conkling, Rebecca G. Bagley, Yamei Wang, Maureen G. Conlan, Peter Kabos	67
4	Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies 2021 ·Targeted Oncology ·Alexander I. Spira, Aaron R. Hansen, Wael A. Harb, Kelly K. Curtis, (unknown), (unknown), (unknown), Bella Ertik, Walid L. Shaib	26
5	A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179 2020 ·Cancer ·Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse, Ziyue Liu, Ahad A. Sadiq, Robin Zoň, Shadia I. Jalal, Goetz Kloecker, Michael Williamson, Karen L. Reckamp, Robert M. Langdon, Ebenezer A. Kio, Ryan D. Gentzler, Bamidele Adesunloye, Wael A. Harb, Radhika Walling, (unknown), Nasser H. Hanna	116
6	P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy 2019 ·Journal of Thoracic Oncology ·Greg Andrew Durm, Sandra K. Althouse, (unknown), (unknown), Salma K. Jabbour, Robin Zoň, Goetz Kloecker, Magali Williamson, Karen L. Reckamp, Ebenezer A. Kio, Robert M. Langdon, Bamidele Adesunloye, Ryan D. Gentzler, Wael A. Harb, Radhika Walling, Christina Yeon, Marianna Koczywas, (unknown)	1
7	Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders 2018 ·Clinical Cancer Research ·Rachel N. Grisham, Kathleen N. Moore, Michael S. Gordon, Wael A. Harb, (unknown), Darragh Halpenny, Vicky Makker, Carol Aghajanian	22
8	P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC 2018 ·Journal of Thoracic Oncology ·Lauren A. Byers, Kathryn A. Gold, Julio A. Peguero, Melissa L. Johnson, Jorge J. Nieva, Wael A. Harb, Alberto Chiappori, James Strauss, David E. Gerber	1
9	A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas 2018 ·Annals of Oncology ·Wael A. Harb, Jeremy S. Abramson, Matthew A. Lunning, André Goy, Kami J. Maddocks, Claudia Lebedinsky, Adrian M. Senderowicz, Patrick Trojer, William D. Bradley, Ian W. Flinn	24
10	P3.02c-027 Phase I and PK Study of the Folate Receptor-Targeted Small Molecule Drug Conjugate (SMDC) EC1456 in Advanced Cancer: Lung Cancer Subset 2017 ·Journal of Thoracic Oncology ·Martin J. Edelman, Jasgit C. Sachdev, Wael A. Harb, (unknown), Ding Wang, Linda L. Garland	3
11	A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2) 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Ralph V. Boccia, Alberto Bessudo, Richy Agajanian, Paul Conkling, Wael A. Harb, Hui Yang, (unknown), Amy Kimball, James R. Berenson	10
12	A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN 2016 ·Annals of Oncology ·David S. Hong, Gerald S. Falchook, Carl Cook, Wael A. Harb, Paul D. Lyne, Patricia McCoon, Minal Mehta, Pat Mitchell, Ganesh Mugundu, Martin Scott, (unknown)	7
13	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma 2015 ·Clinical Cancer Research ·Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael A. Harb, Leo I. Gordon, Robert M. Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying Luan, (unknown), Thorsten Graef, Nancy L. Bartlett	73
14	Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options 2015 ·Cancer Management and Research ·Wael A. Harb	20
15	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer 2014 ·Journal of Clinical Oncology ·Cristina Saura, José Á. García-Sáenz, Binghe Xu, Wael A. Harb, Rebecca Moroose, Timothy Pluard, Javier Cortés, (unknown), Caroline Germa, Kongming Wang, Miguel Martín, José Baselga, Sung‐Bae Kim	103
16	Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide) 2014 ·Annals of Oncology ·Robert Morris, (unknown), R. Wendel Naumann, Neha Shah, Alan H. Maurer, H. William Strausś, J. Michael Uszler, James T. Symanowski, P. R. Ellis, Wael A. Harb	84
17	PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer 2013 ·Journal of Clinical Oncology ·R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Edward A. Sausville, E. Kutarska, Sharad Ghamande, Nashat Gabrail, Stephen DePasquale, Elżbieta Nowara, Lucy Gilbert, Robert H. Gersh, Michael Teneriello, Wael A. Harb, Panagiotis A. Konstantinopoulos, Richard T. Penson, James T. Symanowski, (unknown), Christopher P. Leamon, David Morgenstern, Richard A. Messmann	169
18	A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma 2013 ·Annals of Hematology ·James R. Berenson, James Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, (unknown), Hassan Ghazal, (unknown), Edwin Kingsley, Wael A. Harb, Stephen J. Noga, Youram Nassir, Regina A. Swift, Robert Vescio	34
19	Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung 2012 ·Journal of Thoracic Oncology ·Martin J. Edelman, Wael A. Harb, (unknown), Ralph V. Boccia, Michael Kraut, Philip Bonomi, Barbara A. Conley, John Rogers, Richard A. Messmann, Edward B. Garon	33
20	Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116 2010 ·Journal of Thoracic Oncology ·(unknown), Wael A. Harb, Daniel S. Bradford, José A. Bufill, Sreenivasa Nattam, (unknown), William B. Fisher, Jane E. Latz, Xiaochun Li, Jingwei Wu, Nasser H. Hanna	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact